Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 26;3(3):750-6.
doi: 10.3390/healthcare3030750.

The Importance of the Management of Infectious Complications for Patients with Left Ventricular Assist Device

Michinari Hieda  1 , Makoto Sata  2 , Takeshi Nakatani  3
Affiliations
Review

The Importance of the Management of Infectious Complications for Patients with Left Ventricular Assist Device

Michinari Hieda et al. Healthcare (Basel). .

Abstract

A left ventricular assist device (LVAD) therapy is the viable option for patients with advanced heart failure as a bridge to transplantation, bridge to recovery, or destination therapy. Although application of LVAD support has become a standard option, serious complications or adverse events related with LVAD remain a concern. LVAD-related infection including driveline infection (DLI) and bloodstream infection (BSI) is one of the serious clinical matters for LVAD patients, and especially BSI leads to the high incidence of mortality. The LVAD-related infections negatively impact patient's quality of life. Therefore, control of infection is one of the primary goals of management in LVAD patients. Several efforts including early and appropriate intervention including antibiotics and wound care may contribute to avert the progress into BSI from localized DLI. Particularly, there are clinical secrets in how to use antibiotics and how to treat wound care in LVAD patients. The rational way of thinking for wound care will be introduced in this review.

Keywords: BSI; DLI; LVAD; Left Ventricular Assist Device; bloodstream infection; drive-line infection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tsiouris A., Paone G., Nemeh H.W., Brewer R.J., Borgi J., Hodari A., Morgan J.A. Lessons learned from 150 continuous-flow left ventricular assist devices: A single institutional 7 year experience. ASAIO J. 2015;61:266–273. doi: 10.1097/MAT.0000000000000191. - DOI - PubMed
    1. Trachtenberg B.H., Cordero-Reyes A., Elias B., Loebe M. A review of infections in patients with left ventricular assist devices: Prevention, diagnosis and management. Methodist Debakey Cardiovasc. J. 2015;11:28–32. doi: 10.14797/mdcj-11-1-28. - DOI - PMC - PubMed
    1. Miller L.W., Pagani F.D., Russell S.D., John R., Boyle A.J., Aaronson K.D., Conte J.V., Naka Y., Mancini D., Delgado R.M., et al. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med. 2007;357:885–896. doi: 10.1056/NEJMoa067758. - DOI - PubMed
    1. Holman W.L., Park S.J., Long J.W., Weinberg A., Gupta L., Tierney A.R., Adamson R.M., Watson J.D., Raines E.P., Couper G.S., et al. Infection in permanent circulatory support: experience from the REMATCH trial. J. Heart Lung Transplant. 2004;23:1359–1365. doi: 10.1016/j.healun.2003.09.025. - DOI - PubMed
    1. Sacar M., Sacar S., Kaleli I., Cevahir N., Teke Z., Kavas S.T., Asan A., Aytekin F.O., Baltalarli A., Turgut H. Efficacy of linezolid in the treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus: an experimental study. Int. J. Infect. Dis. 2008;12:396–401. doi: 10.1016/j.ijid.2007.09.017. - DOI - PubMed

LinkOut - more resources